Compare FEMY & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEMY | NSRX |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 25.8M |
| IPO Year | 2021 | N/A |
| Metric | FEMY | NSRX |
|---|---|---|
| Price | $0.47 | $3.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.50 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 363.1K | 107.6K |
| Earning Date | 05-08-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,293,313.00 | N/A |
| Revenue This Year | $105.16 | N/A |
| Revenue Next Year | $200.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.77 | N/A |
| 52 Week Low | $0.31 | $1.98 |
| 52 Week High | $1.16 | $9.99 |
| Indicator | FEMY | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.01 | 53.67 |
| Support Level | $0.33 | $2.16 |
| Resistance Level | $0.58 | $4.49 |
| Average True Range (ATR) | 0.03 | 0.50 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 94.53 | 40.97 |
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.